1. Home
  2. CRBP vs BW Comparison

CRBP vs BW Comparison

Compare CRBP & BW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRBP
  • BW
  • Stock Information
  • Founded
  • CRBP 2009
  • BW 1867
  • Country
  • CRBP United States
  • BW United States
  • Employees
  • CRBP N/A
  • BW N/A
  • Industry
  • CRBP Biotechnology: Pharmaceutical Preparations
  • BW Building Products
  • Sector
  • CRBP Health Care
  • BW Industrials
  • Exchange
  • CRBP Nasdaq
  • BW Nasdaq
  • Market Cap
  • CRBP 114.8M
  • BW 119.1M
  • IPO Year
  • CRBP N/A
  • BW N/A
  • Fundamental
  • Price
  • CRBP $16.22
  • BW $3.75
  • Analyst Decision
  • CRBP Strong Buy
  • BW Strong Buy
  • Analyst Count
  • CRBP 8
  • BW 1
  • Target Price
  • CRBP $50.57
  • BW $5.00
  • AVG Volume (30 Days)
  • CRBP 221.8K
  • BW 2.9M
  • Earning Date
  • CRBP 11-06-2025
  • BW 11-11-2025
  • Dividend Yield
  • CRBP N/A
  • BW N/A
  • EPS Growth
  • CRBP N/A
  • BW N/A
  • EPS
  • CRBP N/A
  • BW N/A
  • Revenue
  • CRBP N/A
  • BW $724,905,000.00
  • Revenue This Year
  • CRBP N/A
  • BW N/A
  • Revenue Next Year
  • CRBP $220.00
  • BW $8.02
  • P/E Ratio
  • CRBP N/A
  • BW N/A
  • Revenue Growth
  • CRBP N/A
  • BW 48.90
  • 52 Week Low
  • CRBP $4.64
  • BW $0.22
  • 52 Week High
  • CRBP $20.77
  • BW $3.83
  • Technical
  • Relative Strength Index (RSI)
  • CRBP 76.29
  • BW 63.90
  • Support Level
  • CRBP $15.00
  • BW $3.19
  • Resistance Level
  • CRBP $16.97
  • BW $3.83
  • Average True Range (ATR)
  • CRBP 1.01
  • BW 0.34
  • MACD
  • CRBP 0.28
  • BW 0.01
  • Stochastic Oscillator
  • CRBP 88.62
  • BW 89.50

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About BW Babcock & Wilcox Enterprises Inc.

Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.

Share on Social Networks: